Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy language in Blueprint Medicines’ SEC documents can feel like decoding a genomic sequence. Pipeline updates on selective kinase therapies, milestone payments from collaborations, and cash-runway disclosures are scattered across hundreds of pages. If finding that information in a 10-K or spotting insider buys before an FDA catalyst seems daunting, you’re not alone.
Stock Titan solves the problem. Our platform delivers AI-powered summaries that translate complex biotech terminology into plain English, then links you straight to the source form. Need the Blueprint Medicines quarterly earnings report 10-Q filing? One click. Curious about Blueprint Medicines insider trading Form 4 transactions or real-time alerts for Blueprint Medicines Form 4 insider transactions real-time? We surface them instantly. From a Blueprint Medicines annual report 10-K simplified to a Blueprint Medicines 8-K material events explained, our AI highlights what moves the stock.
Here’s what you can do on this page:
- Review every 10-K, 10-Q and 8-K with side-by-side Blueprint Medicines earnings report filing analysis
- Track Blueprint Medicines executive stock transactions Form 4 and monitor patterns before clinical readouts
- Dive into the Blueprint Medicines proxy statement executive compensation to see how management is rewarded for pipeline milestones
- Use our natural-language search—“understanding Blueprint Medicines SEC documents with AI” returns plain-spoken answers, not PDFs
Every filing posts within minutes of hitting EDGAR, and our expert layer explains valuation drivers like clinical trial spend, collaboration revenue and patent updates. Complex biotech filings, now clear and actionable.
Conagra Brands EVP & Chief Supply Chain Officer Alexandre Eboli filed a Form 4 for transactions between 17 and 20 Jul 2025.
- Common stock: 37,091 shares were issued via long-term incentive and RSU vesting, while 14,351 shares were withheld for taxes at ≈$19, yielding a net gain of 22,740 shares. Direct ownership now stands at 52,771 shares.
- Derivative securities: A new award of 36,022 restricted stock units (RSUs) was granted; these vest 33.33 % on 17 Jul 2026 and 2027 and 33.34 % on 17 Jul 2028. After converting earlier awards, Eboli retains 36,022 unvested RSUs.
No open-market sales occurred—disposals were strictly tax withholdings. The filing reflects routine equity compensation activity that modestly increases the insider’s exposure to CAG shares.
Conagra Brands (CAG) Form 4 – insider activity by SVP & Corporate Controller William Eric Johnson. On 17 Jul 2025 the executive received 10,006 new restricted stock units (RSUs) that will vest in three equal tranches from 2026-2028. RSU vesting triggered two same-day exercises (Code M):
- 19 Jul 2025: 1,516 shares issued; 450 shares automatically sold/withheld for taxes at $19.07.
- 20 Jul 2025: 3,469 shares issued; 1,018 shares withheld at $19.07.
Form 4 filed for Blueprint Medicines (BPMC) shows Chief Medical Officer Dr. L. Becker divesting his entire equity stake on 17 Jul 2025 in conjunction with Sanofi’s takeover. A total of 51,772 common shares, 1,607 RSU/PSU shares and 115,001 stock-option shares were cancelled and converted into the merger consideration of $129.00 in cash plus one CVR per share.
The filing confirms that a Sanofi subsidiary completed its tender offer and merged with BPMC, making the company an indirect wholly owned unit of Sanofi. Pre-2025 awards were paid out immediately, while 2025 grants convert to cash-based awards that continue vesting under Sanofi. Following settlement, Dr. Becker reports 0 shares and 0 options, implying Section 16 reporting will cease. The document largely serves as legal confirmation that the acquisition closed and insider equity has been fully cashed out.
Form 4 filed for Blueprint Medicines (BPMC) shows Chief Medical Officer Dr. L. Becker divesting his entire equity stake on 17 Jul 2025 in conjunction with Sanofi’s takeover. A total of 51,772 common shares, 1,607 RSU/PSU shares and 115,001 stock-option shares were cancelled and converted into the merger consideration of $129.00 in cash plus one CVR per share.
The filing confirms that a Sanofi subsidiary completed its tender offer and merged with BPMC, making the company an indirect wholly owned unit of Sanofi. Pre-2025 awards were paid out immediately, while 2025 grants convert to cash-based awards that continue vesting under Sanofi. Following settlement, Dr. Becker reports 0 shares and 0 options, implying Section 16 reporting will cease. The document largely serves as legal confirmation that the acquisition closed and insider equity has been fully cashed out.
Form 4 filed for Blueprint Medicines (BPMC) shows Chief Medical Officer Dr. L. Becker divesting his entire equity stake on 17 Jul 2025 in conjunction with Sanofi’s takeover. A total of 51,772 common shares, 1,607 RSU/PSU shares and 115,001 stock-option shares were cancelled and converted into the merger consideration of $129.00 in cash plus one CVR per share.
The filing confirms that a Sanofi subsidiary completed its tender offer and merged with BPMC, making the company an indirect wholly owned unit of Sanofi. Pre-2025 awards were paid out immediately, while 2025 grants convert to cash-based awards that continue vesting under Sanofi. Following settlement, Dr. Becker reports 0 shares and 0 options, implying Section 16 reporting will cease. The document largely serves as legal confirmation that the acquisition closed and insider equity has been fully cashed out.
Form 4 filed for Blueprint Medicines (BPMC) shows Chief Medical Officer Dr. L. Becker divesting his entire equity stake on 17 Jul 2025 in conjunction with Sanofi’s takeover. A total of 51,772 common shares, 1,607 RSU/PSU shares and 115,001 stock-option shares were cancelled and converted into the merger consideration of $129.00 in cash plus one CVR per share.
The filing confirms that a Sanofi subsidiary completed its tender offer and merged with BPMC, making the company an indirect wholly owned unit of Sanofi. Pre-2025 awards were paid out immediately, while 2025 grants convert to cash-based awards that continue vesting under Sanofi. Following settlement, Dr. Becker reports 0 shares and 0 options, implying Section 16 reporting will cease. The document largely serves as legal confirmation that the acquisition closed and insider equity has been fully cashed out.
Form 4 discloses that Chief Scientific Officer Percy H. Carter no longer holds Blueprint Medicines (BPMC) equity following the 17 July 2025 closing of the company’s merger with Sanofi. Under the Agreement and Plan of Merger, Sanofi’s subsidiary paid $129.00 in cash plus one contingent value right (CVR) for each BPMC share.
Equity conversions at the merger’s effective time ("Effective Time"):
- Common stock: 21,353 performance-based PSUs were deemed earned (code A) and 56,614 shares were tendered (code D). Remaining 17,894 shares were also converted, leaving 0 shares beneficially owned.
- Equity awards: 128,700 stock options (exercise prices $43.15-$96.57) were fully vested, cancelled and exchanged for the cash/CVR package.
- All outstanding RSUs and the cash-settled portions of 2025 PSUs/RSUs/options will continue to vest in cash & CVRs as specified in the merger agreement.
The filing confirms mechanical settlement of insider holdings and signals completion of Sanofi’s acquisition, with Blueprint Medicines now an indirect wholly owned Sanofi subsidiary.
Form 4 discloses that Chief Scientific Officer Percy H. Carter no longer holds Blueprint Medicines (BPMC) equity following the 17 July 2025 closing of the company’s merger with Sanofi. Under the Agreement and Plan of Merger, Sanofi’s subsidiary paid $129.00 in cash plus one contingent value right (CVR) for each BPMC share.
Equity conversions at the merger’s effective time ("Effective Time"):
- Common stock: 21,353 performance-based PSUs were deemed earned (code A) and 56,614 shares were tendered (code D). Remaining 17,894 shares were also converted, leaving 0 shares beneficially owned.
- Equity awards: 128,700 stock options (exercise prices $43.15-$96.57) were fully vested, cancelled and exchanged for the cash/CVR package.
- All outstanding RSUs and the cash-settled portions of 2025 PSUs/RSUs/options will continue to vest in cash & CVRs as specified in the merger agreement.
The filing confirms mechanical settlement of insider holdings and signals completion of Sanofi’s acquisition, with Blueprint Medicines now an indirect wholly owned Sanofi subsidiary.
Blueprint Medicines (BPMC) – Form 4 key points
Director Alexis Borisy reported the full disposition of his equity on 17 Jul 2025, the date Sanofi’s acquisition of Blueprint closed. Each share of common stock was exchanged for $129.00 cash plus one contingent value right (CVR) under the previously announced Merger Agreement. Table I records the tender of 74,160 shares (Code “U”), leaving 0 shares owned after the transaction. Table II shows cancellation of 46,545 stock options struck between $50.64 and $106.14; options became fully vested and converted into the right to receive the cash spread versus strike price plus one CVR per optioned share.
All restricted stock units were likewise canceled for the same consideration. As a result, Borisy now holds no direct or indirect interest in Blueprint securities, and Blueprint has become an indirect wholly owned subsidiary of Sanofi. The filing is administrative, confirming completion of the takeover rather than signaling new operational or valuation information.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
What is Blueprint Medicines Corp focused on?
How does the company differentiate its approach in drug discovery?
What are the core therapeutic areas of Blueprint Medicines?
How does Blueprint Medicines generate revenue?
What is unique about their research and development process?
How does Blueprint Medicines address unmet medical needs?
What role do kinase inhibitors play in their treatment strategy?
How does the company maintain its market position?
